Discrepancies in Control Group Mortality Rates Within Studies Assessing Topical Antibiotic Strategies to Prevent Ventilator-Associated Pneumonia: An Umbrella Review

James C. Hurley, MD, PhD, FRACP1,2

Objectives: To test the postulate that concurrent control patients within ICUs studying topical oropharyngeal antibiotics to prevent ventilator-associated pneumonia and mortality would experience spillover effects from the intervention.

Data Sources: Studies cited in 15 systematic reviews of various topical antibiotic and other infection prevention interventions among ICU patients.

Study Selection: Studies of topical antibiotics, stratified into concurrent control versus nonconcurrent control designs. Studies of nondecontamination-based infection prevention interventions provide additional points of reference. Studies with no infection prevention intervention provide the mortality benchmark. Data from additional studies and data reported as intention to treat were used within sensitivity tests.

Data Extraction: Mortality incidence proportion data, mortality census, study characteristics, group mean age, ICU type, and study publication year.

Data Synthesis: Two-hundred six studies were included. The summary effect sizes for ventilator-associated pneumonia and mortality prevention derived in the 15 systematic reviews were replicated. The mean ICU mortality incidence for concurrent control groups of topical antibiotic studies (28.5%; 95% CI, 25.0–32.3; n = 41) is higher versus the benchmark (23.7%; 19.2–28.5%; n = 34), versus nonconcurrent control groups (23.5%; 19.3–28.3; n = 14), and versus intervention groups (24.4%; 22.1–26.9; n = 62) of topical antibiotic studies. In meta-regression models adjusted for group-level characteristics such as group mean age and publication year, concurrent control group membership within a topical antibiotic study remains associated with higher mortality (p = 0.027), whereas other group memberships, including membership within an antiseptic study, are each neutral (p = not significant).

Conclusions: Within topical antibiotic studies, the concurrent control group mortality incidence proportions are inexplicably high, whereas the intervention group mortality proportions are paradoxically similar to a literature-derived benchmark. The unexplained ventilator-associated pneumonia and mortality excess in the concurrent control groups implicates spillover effects within studies of topical antibiotics. The apparent ventilator-associated pneumonia and mortality prevention effects require cautious interpretation.

Key Words: antibiotic prophylaxis; intensive care units; mechanical ventilation; mortality; study design; topical antibiotics

The incidence of ventilator-associated pneumonia (VAP) among patients requiring prolonged (> 24 hr) ICU stay and methods for its prevention have been extensively studied (1–19). Oropharyngeal applications of topical antibiotics, with (selective digestive decontamination [SDD]) or without (selective oropharyngeal decontamination) protocolized parenteral antibiotic prophylaxis (PPAP), appear highly effective, with apparent reductions typically being ~50% for VAP and ~10–20% for mortality (10–16). By contrast, nondecontamination-based methods achieve less than 50%
MATERIALS AND METHODS
Being an analysis of published work, ethics committee review of this study was not required.

Study Selection and Decant of Groups
The literature search and study decant used here is in four steps as detailed in Figure S1 (Supplemental Digital Content 1, http://links.lww.com/CCX/A129).

The inclusion criteria were study citation in one of 15 systematic reviews or meta-analyses with incidence data for mortality extractable as an incidence proportion with the denominator being the numbers of mechanically ventilated (MV) patients with an ICU stay of at least 24 hours. Additional more recent studies were obtained using the “Related articles” function within Google Scholar to use as tests of sensitivity. The exclusion criteria were as follows: studies restricted to specific patient populations such as studies limited to patients with the acute respiratory distress syndrome, pancreatitis, cardiothoracic or liver transplantation surgery, and studies of pediatric populations. Also, studies in which less than 50% of patients received MV, studies with fewer than 30 patients overall, studies which reported zero mortality, studies limited to parenteral antibiotic prophylaxis as the study intervention, and case-control studies were excluded.

The studies were classified on the basis of whether the study intervention was a topical oropharyngeal antibiotic regimen, a topical oropharyngeal antisect regimen, a nondecontamination intervention or no intervention (observational studies). The studies of nondecontamination methods of infection prevention, including VAP (ventilator associated pneumonia) prevention, encompass a broad range of methods delivered via the gastric route, the airway route, or the oral care route. Within the topical antibiotic studies, any group receiving topical oropharyngeal antibiotic was regarded as an intervention group and all other groups were regarded as a control group regardless of other interventions including receipt of PPAP. The control groups from these studies were stratified into NCC and CC groups.

Outcomes of Interest
The VAP or ICU mortality incidence was calculated as the number of patients with respectively VAP or ICU mortality per 100 patients. Each incidence was expressed as a proportion using the total number of patients as the denominator. In addition, the following were also extracted where available: whether less than 90% (an arbitrary threshold) of patients received MV, whether the ICU was a trauma ICU, being defined here as having greater than 50% of patients admitted for trauma, the group mean (or median) age, year of study publication, and whether the component group was exposed to PPAP. Late mortality, defined here as hospital mortality or mortality later than day 21, was used in a sensitivity analysis for studies without ICU mortality data.

Study Effect Sizes
The study specific and overall summary effect sizes and associated 95% CI for each category of intervention were calculated using the DerSimonian and Laird random-effect methods of meta-analysis using the “metan” command in Stata 15.1 (Stata Corp., College Station, TX).

Benchmarking: Visual
Caterpillar plots were generated to facilitate a visual benchmark of the mortality incidence proportions.
These were generated as follows: the data for mortality were logit transformed to generate caterpillar plots using the "metan" command in Stata as previously. For mortality, this transformation proceeds as follows: with the number of patients as the denominator (D), the number of patients who die as the numerator (N), and R being the mortality proportion (N/D), the logit(mortality) is log(N/(D–N)) and its variance is 1/(D × R × [1–R]). Note that for any group with a zero event rate (N = 0), the addition of the continuity correction (i.e., N + 0.5) is required to avoid indeterminate transformations of the logit proportion and its variance. The visual benchmark is the summary incidence for ICU mortality as derived using the observational studies. This visual benchmark was then used in the respective caterpillar plots of the component groups from the VAP prevention studies as a reference line. Dot plots were used to provide an "at a glance" summary of the entire evidence base. These were derived as above for caterpillar plots but without the confidence limits.

**Benchmarking: Meta-Regression**

Group-level regression models of VAP and mortality proportions were developed using meta-regression methods using DerSimonian and Laird random-effects methods using the "metareg" command in Stata (27). In these regression models, the category of observational groups acts as the reference (benchmark) category in each model. The following group-level factors were entered into the meta-regression model: component group type; PPAP use; greater than 90% receiving MV; trauma ICU; group mean (or median) age; and year of study publication. In addition, mode of VAP diagnosis and mortality census time were entered into the VAP and mortality models, respectively. All factors were entered into the meta-regression models without any preselection step.

The regression models were repeated using generalized estimating equation methods ("xtgee" command in Stata). There were three sensitivity tests of the findings. The meta-regression was repeated using intention to treat (ITT) data from eight studies of topical antibiotic-based methods as recorded within the most recent Cochrane review (13). The meta-regression was repeated using exclusion criteria, are listed in Tables S1–S4 (Supplemental Digital Content 1, http://links.lww.com/CCX/A129). Most studies were published between 1990 and 2010 and a minority contained patient groups for which fewer than 90% received MV or originated from trauma ICUs (Table 1).

Component groups were decanted from observational studies (Table S1, Supplemental Digital Content 1, http://links.lww.com/CCX/A129), studies of various nondecontamination methods of VAP prevention (Table S2, Supplemental Digital Content 1, http://links.lww.com/CCX/A129), studies of topical antiseptic-based methods (Table S3, Supplemental Digital Content 1, http://links.lww.com/CCX/A129), and studies of topical antibiotic-based methods (Table S4, Supplemental Digital Content 1, http://links.lww.com/CCX/A129). The nondecontamination interventions (Table S2, Supplemental Digital Content 1, http://links.lww.com/CCX/A129) include the following: use or nonuse of different gastric acid inhibitors; feeding by the gastric versus the small bowel route; open versus closed tracheal suction; kinetic bed therapy versus not; subglottic secretion drainage; vitamin D supplementation; and various ventilation strategies. There were 32 different topical antibiotic regimens and four different types of topical antiseptic interventions. Group mean age ranged between 27 and 72 years and was similar across all four categories of study.

**Effect Sizes**

Of the three categories of intervention, the largest summary effect size for VAP prevention was that associated with topical antibiotic methods (Table 1; Figs. S2–S4 and Table S6, Supplemental Digital Content 1, http://links.lww.com/CCX/A129). A significant mortality prevention effect size was apparent only for the category of topical antibiotic-based interventions and not for the other two intervention categories (Table S7, Supplemental Digital Content 1, http://links.lww.com/CCX/A129). The mortality prevention effect size estimates were in each case comparable to various estimates in the 15 systematic reviews from which the studies had been drawn (Table 1; Table S7 and Figs. S6–S8, Supplemental Digital Content 1, http://links.lww.com/CCX/A129).

**Visual Benchmarking**

The mean VAP incidence proportion derived from studies without an intervention (observational studies) was 26.1 per 100 patients. There was a difference of more than eight percentage points between the mean VAP incidence derived among the four intervention categories (Table 1; Fig. S5, Supplemental Digital Content 1, http://links.lww.com/CCX/A129). By contrast, the mean VAP incidence derived from each of the three categories of intervention group differed from each other by less than four percentage points.

The ICU mortality incidence proportion is displayed for individual study groups (Figs. 2–4; Figs. S9–S14, Supplemental Digital Content 1, http://links.lww.com/CCX/A129) and in summary (Table 1). Of note, the mean mortality proportions for CC control groups of topical antibiotic studies and for topical antiseptic intervention groups are each more than four percentage points higher versus the ICU mortality benchmark derived from the observational groups, whereas that for each other category differed in each case nonsignificantly from the benchmark by less than three percentage points. By contrast, the mean ICU mortality incidence proportion for intervention groups of topical antibiotic studies and also NCC control groups were each within one percentage point of the benchmark.

A linear regression line of ICU mortality proportion versus group mean age was derived using the observational groups (Fig. S15, Supplemental Digital Content 1, http://links.lww.com/CCX/A129).
TABLE 1. Characteristics of Studies

| Characteristics | Observational | Nondecontamination | Topical Antiseptic | Topical Antibiotic Studies |
|-----------------|---------------|---------------------|--------------------|---------------------------|
| Study characteristics | | | | |
| Listing | Table S1 (Supplemental Digital Content 1, http://links.lww.com/CCX/A129) | Table S2 (Supplemental Digital Content 1, http://links.lww.com/CCX/A129) | Table S3 (Supplemental Digital Content 1, http://links.lww.com/CCX/A129) | Table S4 (Supplemental Digital Content 1, http://links.lww.com/CCX/A129) |
| Number of studies | 43 | 81 | 22 | 64 |
| Mechanical ventilation for > 48 hr for < 90% | 4 | 2 | 2 | 6 |
| Protocolized parenteral antibiotic prophylaxis for control groups | 0 | 0 | 0 | 6 |
| Trauma ICUs | 7 | 20 | 2 | 17 |
| Late mortality census | 9 | 14 | 2 | 10 |
| North American ICU | 12 | 24 | 3 | 5 |
| Study publication year (range) | 1986–2019 | 1985–2015 | 2000–2018 | 1973–2018 |
| Group characteristics | | | | |
| Numbers of patients per study group, median (IQR) | 278 (175–487) | 63 (44–100) | 65 (31–114) | 80 (41–131) |
| Mean patient age per study group, median (IQR) | 58 (51–63) | 56 (49–60) | 55 (47–58) | 54 (45–61) |
| VAP prevention effect, OR (95% CI) (n) | NA | 0.69 (0.63–0.76) (71); Figure S2 (Supplemental Digital Content 1, http://links.lww.com/CCX/A129) | 0.76 (0.64–0.9) (19); Figure S3 (Supplemental Digital Content 1, http://links.lww.com/CCX/A129) | 0.37 (0.34–0.41) (59); Figure S4 (Supplemental Digital Content 1, http://links.lww.com/CCX/A129) |
| VAP incidence per 100 patients, mean (95% CI) (n) | 26.1 (23.3–29.1) (42) | 24.1 (21.4–26.9) (72) | 25.5 (19.6–32.5) (17) | 34.5 (29.1–40.4) (14) |
| Mortality prevention effect, OR (95% CI) (n) | NA | 0.97 (0.90–1.04) (86); Figure S6 (Supplemental Digital Content 1, http://links.lww.com/CCX/A129) | 1.04 (0.95–1.15) (24); Figure S7 (Supplemental Digital Content 1, http://links.lww.com/CCX/A129) | 0.91 (0.87–0.96) (69); Figure S8 (Supplemental Digital Content 1, http://links.lww.com/CCX/A129) |
| ICU mortality incidence per 100 patients, mean (95% CI) (n) | 23.7* (19.2–28.5) (34); Figure S9 (Supplemental Digital Content 1, http://links.lww.com/CCX/A129) | 23.6 (21.4–26.3) (72); Figure S10 (Supplemental Digital Content 1, http://links.lww.com/CCX/A129) | 26.3 (20.8–33.0) (12); Figure S12 (Supplemental Digital Content 1, http://links.lww.com/CCX/A129) | 28.5* (25.0–32.3) (41); Figures 3 and S13 (Supplemental Digital Content 1, http://links.lww.com/CCX/A129) |

(Continued)
Critical Care Explorations

TABLE 1. (Continued). Characteristics of Studies

| Characteristics            | Observational | Nondecontamination | Topical Antiseptic | Topical Antibiotic Studies |
|----------------------------|---------------|--------------------|-------------------|---------------------------|
| Interventions groups       | 22.3 (20.3–24.4) | (74); Figure S11 | 28.3 (24.6–32.1) | 24.4<sup>j</sup> (22.1–26.9) (62); Figures 4 and S14 |
| (Supplemental Digital Content 1, http://links.lww.com/CCX/A129) |               |                    |                   | (Supplemental Digital Content 1, http://links.lww.com/CCX/A129) |

IQR = interquartile range, NA = not applicable, OR = odds ratio, VAP = ventilator-associated pneumonia.

Note, 31 studies had more than one observational, control, or intervention group and four studies provided both concurrent control and nonconcurrent control groups. Hence, the number of groups does not equal the number of studies.

<sup>a</sup>Studies for which less than 90% of patients were reported to receive > 48 hr of mechanical ventilation.

<sup>b</sup>Protocolized parenteral antibiotic prophylaxis (PPAP) was used within six control and 36 intervention groups.

<sup>c</sup>Trauma ICU arbitrarily defined as an ICU with more than 50% of admissions for trauma.

<sup>d</sup>Late mortality is either hospital or beyond day 21 mortality census vs ICU mortality census.

<sup>e</sup>Data are median and IQR.

<sup>f</sup>Group mean age was not available for 48 groups.

<sup>g</sup>VAP incidence or effect size was not available for 27 studies.

<sup>h</sup>VAP incidence—topical antibiotic alone intervention groups; 15.3 (11.1–18.4) (34).

<sup>i</sup>VAP incidence—topical antibiotic + PPAP intervention groups; 13.2 (9.8–17.8) (32).

<sup>j</sup>IUC mortality or effect size was not available for 35 studies.

<sup>k</sup>This is the ICU mortality benchmark as derived in Figure S9 (Supplemental Digital Content 1, http://links.lww.com/CCX/A129).

<sup>l</sup>IUC mortality incidence—including intention to treat (ITT) data as in Table S6 (Supplemental Digital Content 1, http://links.lww.com/CCX/A129); 25.0 (22.6–27.7) (63).

The control and intervention groups from all study categories, with one exception, are distributed symmetrically versus this regression line. By contrast, CC groups from studies of antibiotic-based methods are mostly above this regression line (Figs. S15–S17, Supplemental Digital Content 1, http://links.lww.com/CCX/A129).

Statistical Benchmarking

In meta-regression models for VAP and for mortality (Table 2), membership of each category of intervention group was associated with a lower VAP incidence (p < 0.02), whereas no intervention group category was associated with lower mortality (p = not significant).

Strikingly, membership of a CC group of a topical antibiotic study was associated with higher mortality (p = 0.027). The size of this association exceeded that associated with 10 years difference in group mean age. By contrast, membership of no other category of component group was associated a significant effect in the mortality model.

ITT data reporting an additional 103 deaths among 263 patients (39%) from eight CC design studies of topical antibiotics as reported within one systematic review (13) are listed in Table S5 (Supplemental Digital Content 1, http://links.lww.com/CCX/A129). The ITT mortality incidence proportions among the control and intervention groups are between 2 and 20 percentage points higher than the published data (as in Table S4, Supplemental Digital Content 1, http://links.lww.com/CCX/A129) of these studies. Using these ITT data in the meta-regression fails to change the findings (data not shown). Two other sensitivity tests as listed in the methods gave similar findings to the base analysis (Table 2).

DISCUSSION

This analysis benchmarks the ICU mortality incidences in the component groups of studies, drawn mostly from 15 systematic reviews (1–15), for three broad categories of VAP prevention methods versus a benchmark derived using the ICU mortality data from observational studies of MV patients. Each of the three broad categories of intervention appears effective in preventing VAP among patients receiving MV, whereas a significant mortality prevention effect was apparent only for the topical antibiotic-based methods. This analysis is undertaken to address the question of possible spillover effects associated with the use of topical antibiotics as infection prevention, as originally postulated (19).

Of note, the mortality effect sizes estimated here are each broadly comparable to those reported in the systematic reviews from which the studies were sourced (Table S7, Supplemental Digital Content 1, http://links.lww.com/CCX/A129). However, in addition to the discrepancy between the results of topical antibiotics studies using CC design versus studies of topical antibiotics using NCC design, there are three observations which suggest spillover effects from the topical oropharyngeal antibiotic intervention used within these VAP prevention studies.

First, there is a nearly five percentage point excess mortality in the CC control groups of the topical antibiotic studies versus the benchmark, whereas the overall mean mortality in the categories of intervention and NCC control groups of the topical antibiotic studies are each within one percentage point of the benchmark. Furthermore, the mean ICU mortality incidence for all other categories of component group, with the exception of topical antiseptic intervention groups (see below), differs from the benchmark by less than three percentage points.

Second, the ICU mortality incidence for CC groups is generally higher than expected (Fig. 3) and higher than expected versus group mean age (Figs. S16 and S17, Supplemental Digital Content...
The pattern of the discrepancy is also contrary in two ways to the general pattern for results of CC and NCC design studies of the same topic (28). In general, in the investigation of new therapies, trials that have used historic controls are more likely to report a benefit than are randomized trials (28). Furthermore, this difference can be attributed to inequalities in the prognostic factors among the historic control groups in comparison with randomized control groups with a worse outcome for the historic control groups as a consequence. By contrast, the conflicting results of CC versus NCC studies of SDD are doubly discrepant to these patterns.

There are six key limitations to this analysis, the first being that, intentionally, there was considerable heterogeneity in the interventions, populations, mean group age, and study designs among the studies included here. This heterogeneity reflects the broad mix of patient populations within the studies of the 15 systematic reviews. Hence, the summary effect sizes derived here as displayed in Figs. S2–S4, S6–S8, and Tables S6 and S7 (Supplemental Digital Content 1, http://links.lww.com/CCX/A129) are indicative only.

Second, the studies have been published over a period of 30 years. However, the mortality incidence varied nonsignificantly with year of publication in the meta-regression model.

The fourth limitation is that in estimating ICU mortality incidence, competing risks such as ICU discharge and patient exclusion due to early mortality, would likely cause underestimation of group mortality. For example, the additional ITT data cited in one systematic review (13) arose from several studies of topical antibiotics, which excluded patients usually because the patient died before completing the course of topical antibiotic prophylaxis (or matching control). Although the overall impact of these competing risk biases is uncertain, of note, the inclusion or not of mortality data from studies which have only late mortality data, and also inclusion or not of ITT data from eight studies, gave similar findings within the meta-regression models (Table 2 and data not shown).

Furthermore, this analysis was mostly limited to studies listed within 15 systematic reviews. Systematic reviews typically exclude those studies with only NCC-group patients due to

![Figure 2. The ICU mortality incidence for the component (C = control, CC = concurrent control, I = intervention, NCC = nonconcurrent control) groups of studies of nondecontamination, topical antiseptic, or topical antibiotic-based methods versus the benchmark being the summary mean (central vertical line) derived from the observation studies (Ob = observational) together with the 95% confidence limits (horizontal error bars) associated with the summary incidence. Shown are incidences from all intervention groups (solid triangles), control groups and observational group incidences (open circles), and control groups that received protocolized parenteral antibiotic prophylaxis (PPAP) (solid squares). The ICU mortality incidence data are displayed in more detail as caterpillar plots (Figs. S9–S14, Supplemental Digital Content 1, http://links.lww.com/CCX/A129). SDD = selective digestive decontamination, SOD = selective oropharyngeal decontamination.](http://links.lww.com/CCX/A129)
their low-quality scores. Hence, to minimize the risk of missing some NCC studies, these and other difficult-to-locate studies were actively sought for sensitivity testing the regression model.

Also, systematic reviews of studies not in the controlled trial format, such as studies of nondrug interventions, have not been included here. For example, a systematic review of 13 “before and after” studies of the impact of ventilator care bundles toward reducing ICU mortality was not included here (29).

Finally, the observational studies, from which the mortality benchmark is derived, are key to this analysis. It is presumed that their mortality experience is generalizable to the prevention studies. Furthermore, none of these observational studies explicitly stated that decontamination strategies were used. It remains possible that decontamination use was a part of the units’ ventilation bundle. This, however, is unlikely as published surveys indicate that SDD was used in less than 5% of European ICU’s over this period of time (30, 31).
A strength of this analysis is that group mean age was available from greater than 200 studies to test as a group-level predictor of ICU mortality risk. Furthermore, the data and results for each individual study are traceable in the Online Data Supplement (Supplemental Digital Content 1, http://links.lww.com/CCX/A129). By contrast, a substantial variation in 28-day group mortality rate was found among 65 trials of sepsis therapies undertaken in the critical care context (32). However, the group mean age varied little across these 65 studies (sd, 3.8 yr), and hence a correlation with 28-day group mortality rate was not demonstrable (32).

Where an intervention appears to prevent ICU-acquired infection within a CC trial, it remains crucial to clarify how much of the effect is due to a direct effect of the intervention on the intervention group patients versus how much may result from any spillover effect of the intervention on the CC control group patients. This question is unanswerable for any one study or even any one systematic review examined in isolation. To clarify the paradoxical observations among the studies of topical antibiotic-based methods noted here would require a large, purpose-designed, cluster randomized trial of topical antibiotics in ICU patients. Such a study would present unique logistic and ethical challenges (33, 34).

The analysis here takes advantage of the NCC versus CC designs of the topical antibiotic studies together with reference to an external benchmark as a type of natural experiment (22, 34) of the postulate that topical antibiotics might influence events among nonintervention (i.e., CC) patients within the

| Factor | Ventilator-Associated Pneumonia | | Mortality |
|--------|-------------------------------|-----------------|-----------------|
|        | Coefficient (95% CI) | p | Coefficient (95% CI) | p |
| Groups from observational studies (reference group) | −1.8 (−2.2 to −1.4) | 0.001 | −1.6 (−1.9 to −1.3) | 0.001 |
| Nondecontamination studies | | | |
| Control groups | −0.25 (−0.52 to +0.02) | 0.07 | −0.03 (−0.23 to +0.17) | 0.78 |
| Intervention groups | −0.67 (−0.94 to −0.40) | 0.001 | −0.10 (−0.30 to +0.10) | 0.31 |
| Antiseptic studies | | | |
| Control groups | −0.11 (−0.54 to +0.32) | 0.61 | +0.29 (−0.05 to +0.63) | 0.09 |
| Intervention groups | −0.47 (−0.86 to −0.09) | 0.017 | +0.21 (−0.08 to +0.50) | 0.16 |
| Topical antibiotic studies | | | |
| Nonconcurrent control groups | +0.35 (−0.10 to +0.79) | 0.13 | +0.01 (−0.29 to +0.30) | 0.96 |
| Concurrent control groups | +0.29 (−0.03 to +0.61) | 0.07 | +0.27 (−0.03 to +0.51) | 0.027 |
| Intervention groups | −0.78 (−1.1 to −0.45) | 0.001 | +0.04 (−0.19 to +0.28) | 0.75 |
| Protocolized parenteral antibiotic prophylaxis | −0.10 (−0.44 to +0.25) | 0.57 | −0.13 (−0.37 to +0.11) | 0.29 |
| Mechanical ventilation > 90% | +0.67 (−0.34 to +1.00) | 0.001 | +0.28 (−0.07 to +0.49) | 0.007 |
| Trauma ICU | +0.57 (−0.37 to +0.77) | 0.001 | −0.28 (−0.48 to −0.09) | 0.004 |
| Mode of diagnosis | −0.13 (−0.31 to +0.06) | 0.18 | NA | |
| Mortality census | NA | | +0.25 (−0.01 to +0.41) | 0.001 |
| Age (per decade) | NA | | +0.17 (−0.09 to +0.26) | 0.001 |
| Year of publication (per decade) | 0.08 (−0.40 to +0.19) | 0.20 | −0.07 (−0.15 to +0.01) | 0.08 |

NA = not applicable.

aMechanical ventilation > 90%, more than 90% of patients received mechanical ventilation for more than 48 hr.
bInterpretation. For each model, the reference group is the observational study (benchmark) groups and this coefficient equals the difference in logits from 0 (a logit equal to 0 equates to a proportion of 50%; a logit equal to −2.2 equates to a proportion of 10%; a logit equal to −4.6 equates to a proportion of 1%), and the other coefficients represent the difference in logits for groups positive for that factor vs the reference group.
cRepeating the mortality regression model with and without the seven studies found outside of the 15 systematic reviews, and with or without the studies with only late mortality data in the meta-regression model, gave similar findings (data not shown) for each repeat.
dProtocolized parenteral antibiotic prophylaxis is the coefficient for those control or intervention groups receiving protocolized parenteral antibiotic prophylaxis.
eThe coefficient representing the increment for groups for which more than 90% of patients received mechanical ventilation.
fThe coefficient representing the increment for admission to a trauma ICU.
gDiagnosis of ventilator-associated pneumonia by bronchoscopic vs nonbronchoscopic methods.
hHospital or late mortality vs ICU mortality census.
iGroup mean (or median) age with the coefficient representing the increment for a 10-yr increase.
jYear of study publication with the coefficient representing the increment for each decade post 1980.
study ICU as a contextual or spillover effect. Contextual effects, which are of great interest within population-based prevention studies of communicable diseases, are apparent at the individual patient level of analysis and cannot otherwise be estimated (34).

The paradoxical higher mortality noted here for the CC control groups of studies of topical antibiotics aligns with other observations of higher and otherwise unexplained control group incidence of VAP overall (Fig S5, Supplemental Digital Content 1, http://links.lww.com/CCX/A129), VAP associated with Pseudomonas (23), Candida and Acinetobacter (20) and bacteremia overall, Pseudomonas bacteremia (35), Enterococcus bacteremia (22), as well as candidemia (21) and patterns of colonization (36). In each case, the endpoint incidence is higher among CC groups of randomized controlled trials of SDD versus the respective benchmarks and versus the component groups of other studies of MV patients.

It remains to speculate on the potential mechanism of the observations noted here. The generally higher incidence of a range of infection endpoints may indicate inappropriate cross-infection within ICUs using topical antibiotics to prevent infection resulting in a dysbiosis of the ICU microbiome extending to patients exposed to the context of topical antibiotic use within the ICU.

CONCLUSIONS
The incidence of VAP and mortality within the CC groups within studies of topical antibiotics used to prevent ICU-acquired infection are unusually high versus comparable groups in the literature and remains unexplained. This is consistent with negative spillover effects within CC studies causing the apparent prevention effect to be spurious. The inference that topical antibiotics prevent mortality requires cautious interpretation.

REFERENCES
1. Safdar N, Dezfulian C, Collard HR, et al: Clinical and economic consequences of ventilator-associated pneumonia: A systematic review. Crit Care Med 2005; 33:1284–1293
2. Melsen WG, Rovers MM, Bonten MJ: Ventilator-associated pneumonia and mortality: A systematic review of observational studies. Crit Care Med 2009; 37:2709–2718
3. Agrafiotis M, Siempos II, Ntaidou TK, et al: Attributable mortality of ventilator-associated pneumonia: A meta-analysis. Int J Tuberc Lung Dis 2011; 15:1154–1163, i–v
4. Roquilly A, Marret E, Abraham E, et al: Pneumonia prevention to decrease mortality in intensive care unit: A systematic review and meta-analysis. Clin Infect Dis 2015; 60:64–75
5. Melsen WG, Rovers MM, Koeman M, et al: Estimating the attributable mortality of ventilator-associated pneumonia from randomized prevention studies. Crit Care Med 2011; 39:2736–2742
6. Melsen WG, Rovers MM, Groenwold RH, et al: Attributable mortality of ventilator-associated pneumonia: A meta-analysis of individual patient data from randomised prevention studies. Lancet Infect Dis 2013; 13:665–671
7. Putzu A, Belletti A, Cassina T, et al: Vitamin D and outcomes in adult critically ill patients. A systematic review and meta-analysis of randomized trials. J Crit Care 2017; 38:109–114
8. Chan EY, Ruest A, Meade MO, et al: Oral decontamination for prevention of pneumonia in mechanically ventilated adults: Systematic review and meta-analysis. BMJ 2007; 334:889
9. Klompas M, Speck K, Howell MD, et al: Reappraisal of routine oral care with chlorhexidine gluconate for patients receiving mechanical ventilation: Systematic review and meta-analysis. JAMA Intern Med 2014; 174:751–761
10. Price R, MacLennan G, Glen J; SuDDICU Collaboration: Selective digestive or oropharyngeal decontamination and topical oropharyngeal chlorhexidine for prevention of death in general intensive care: Systematic review and network meta-analysis. BMJ 2014; 348:g2197
11. van Nieuwenhoven CA, Buskens E, Van Tiel FH, et al: Relationship between methodological trial quality and the effects of selective digestive decontamination on pneumonia and mortality in critically ill patients. JAMA 2001; 286:335–340
12. Silvestri L, Van Saene HK, Milanesi M, et al: Selective decontamination of the digestive tract reduces bacterial bloodstream infection and mortality in critically ill patients. Systematic review of randomized, controlled trials. J Hosp Infect 2007; 65:187–203
13. Liberati A, D’Amico R, Pifferi, et al: Antibiotic prophylaxis to reduce respiratory tract infections and mortality in adults receiving intensive care. Cochrane Database Syst Rev 2009; 4:Cd000022
14. Pović FCC, Cardinal-Fernandez P, Maia IS, et al: Effect of antibiotics administered via the respiratory tract in the prevention of ventilator-associated pneumonia: A systematic review and meta-analysis. J Crit Care 2019; 43:240–245
15. Plantinga NL, De Smet AMGA, Oostdijk EAN, et al: Selective digestive and oropharyngeal decontamination in medical and surgical ICU patients: Individual patient data meta-analysis. Clin Microbiol Infect 2018; 24:505–513
16. Hurley JC: Prophylaxis with enteral antibiotics in ventilated patients: Selective decontamination or selective cross-infection? Antimicrob Agents Chemother 1995; 39:941–947
17. Wittekamp BH, Plantinga NL, Cooper BS, et al: Decontamination strategies and bloodstream infections with antibiotic-resistant microorganisms in ventilated patients: A randomized clinical trial. JAMA 2018; 320:2087–2098
18. De Smet AMGA, Kluytmans JAJW, Cooper BS, et al: Decontamination of the digestive tract and oropharynx in ICU patients. N Engl J Med 2009; 360:20–31
19. Stoutenbeek CP, Van Saene HK, Miranda DR, et al: The effect of selective decontamination of the digestive tract on colonisation and infection rate in multiple trauma patients. Intensive Care Med 1984; 10:185–192
20. Hurley JC: Paradoxical acinetobacter-associated ventilator-associated pneumonia incidence rates within prevention studies using respiratory tract applications of topical polymyxin: Benchmarking the evidence base. J Hosp Infect 2018; 100:105–113
21. Hurley JC: ICU-acquired candidemia within selective digestive decontamination studies: A meta-analysis. Intensive Care Med 2015; 41:1877–1885
22. Hurley JC: Studies of selective digestive decontamination as a natural experiment to evaluate topical antibiotic prophylaxis and cephalosporin use as population-level risk factors for enterococcal bacteraemia among ICU patients. J Antimicrob Chemother 2019; 74:3087–3094
23. Hurley JC: Incidences of pseudomonas aeruginosa-associated ventilator-associated pneumonia within studies of respiratory tract applications of polymyxin: Testing the Stoutenbeek concurrency postulates. Antimicrob Agents Chemother 2018; 62. pii: e00291–18
24. Hurley JC: Ventilator-associated pneumonia prevention methods using topical antibiotics: Herd protection or herd peril? Chest 2014; 146:890–898
25. Hurley JC: Pro: Selective digestive decontamination is neither safe nor efficacious for critically ill patients. Crit Care Med 2019 Sep 25. [Epub ahead of print]
26. Crawford FW, Morozova O, Buchanan AL, et al: Interpretation of the individual effect under treatment spillover. Am J Epidemiol 2019; 189:1407–1409
27. Harbord RM, Higgins JPT: Meta-regression in stata. Stata J 2008; 8:493–519
28. Sacks H, Chalmers TC, Smith H Jr: Randomized versus historical controls for clinical trials. Am J Med 1982; 72:233–240
29. Pileggi C, Mascaro V, Bianco A, et al: Ventilator bundle and its effects on mortality among ICU patients: A meta-analysis. *Crit Care Med* 2018; 46:1167–1174
30. Bastin AJ, Ryanna KB: Use of selective decontamination of the digestive tract in United Kingdom intensive care units. *Anaesthesia* 2009; 64:46–49
31. Shah R, Louw J, Veenith T: A national survey on current practice of use of selective digestive decontamination in the United Kingdom. *Crit Care* 2008; 12:P7
32. de Grooth HJ, Postema J, Loer SA, et al: Unexplained mortality differences between septic shock trials: A systematic analysis of population characteristics and control-group mortality rates. *Intensive Care Med* 2018; 44:311–322
33. Hurley JC: Is selective decontamination (SDD/SOD) safe in the ICU context? *J Antimicrob Chemother* 2019; 74:1167–1172
34. Hurley JC: How the cluster-randomized trial "works." *Clin Infect Dis* 2020; 70:341–346
35. Hurley JC: Unusually high incidences of pseudomonas bacteremias within topical polymyxin-based decolonization studies of mechanically ventilated patients: Benchmarking the literature. *Open Forum Infect Dis* 2018; 5:ofy256
36. Hurley JC: Inapparent outbreaks of ventilator-associated pneumonia: An ecologic analysis of prevention and cohort studies. *Infect Control Hosp Epidemiol* 2005; 26:374–390